Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Phosplatin Therapeutics

Request full access

Phosplatin Therapeutics is a clinical-stage pharmaceutical company focused on novel therapeutics in oncology

New York City, United StatesFounded 2010Biotech & Life Sciences

About Phosplatin Therapeutics

Phosplatin Therapeutics, which rebranded to Promontory Therapeutics in May 2022, is a privately held, clinical-stage pharmaceutical company focused on developing small molecule immunotherapies for cancer. The company was founded in 2011 following a discovery-stage license transaction with Ohio University for a family of anti-cancer compounds. The co-founders are Robert Fallon, who serves as President and CEO, and Matthew R. Price, the Executive Vice President and COO. Fallon brings extensive global transactional and strategic leadership from his time as Chairman & CEO of The Korea Exchange Bank and head of Asia-Pacific for J.P. Morgan Chase. Price, who met Fallon at Columbia Business School, has a background in strategy, finance, and operations, and was instrumental in negotiating the initial license for the company's main drug development program.

The company's business model centers on the clinical development and eventual commercialization of its proprietary drug candidates. Revenue is generated through private financing and milestone fees from sub-licensing agreements, such as its deal with SciClone Pharmaceuticals for the Greater China market. As a clinical-stage entity, its clients are effectively the patients participating in its numerous clinical trials, with the ultimate goal of serving the broader oncology market upon drug approval. The company has actively conducted research and development in the United States, Europe, and Asia.

Promontory's lead product candidate is PT-112, a novel platinum-pyrophosphate conjugate. This small molecule is designed to work through a distinct mechanism of action that promotes immunogenic cell death (ICD), a process where dying cancer cells trigger an immune response against the tumor. PT-112 is also osteotropic, meaning it naturally targets bone, which is a significant advantage for treating cancers that originate in or metastasize to the bone, such as prostate cancer. The drug has demonstrated anti-cancer activity and a favorable tolerability profile in multiple Phase 1 and Phase 2 clinical trials. These trials are investigating PT-112 as a monotherapy for metastatic castration-resistant prostate cancer (mCRPC) and for rare thymic epithelial tumors, for which it has received FDA Orphan Drug Designation. It is also being studied in combination with PD-L1 checkpoint inhibitors for other cancers.

Source: Dealroom company data

At a glance

Status
Operational
Employees
13
Open positions
None listed
Dealroom signal
68.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Dec 2021 $37M $148M AdInvest · Adinvest AG ↗
ANGELOther financing Aug 2020 $18M $74M Undisclosed ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Phosplatin Therapeutics website traffic

Latest recorded traffic for Phosplatin Therapeutics is 220 monthly website visits, up 15.8% over the last three months. Phosplatin Therapeutics's team declined 7.1% over the past year.

Latest monthly visits220 3-month web change+15.8% 1-year team growth-7.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Phosplatin Therapeutics in the New York City ecosystem

Live from Dealroom

The Phosplatin Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Other known investors1 additional known investor

  • Ohio University
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · New York City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Phosplatin Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Phosplatin Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.